MedTrace Logo

Second Line Bismuth Containing Quadruple Therapy With Supplementary Probiotic

NCT05577572 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-10-21

No results posted yet for this study

Summary

This study is designed to evaluate the clinical outcome of second line Bismuth containing quadruple therapy with supplementary probiotic for Helicobacter pylori eradication

Conditions

  • H.Pylori Gastrointestinal Disease

Interventions

DIETARY_SUPPLEMENT

Probiotics packets

The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Probiotics packets is taken from day 1\~56.

DIETARY_SUPPLEMENT

Placebo packets

The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Placebo packets is taken from day 1\~56.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ming-Lun Han, doctor · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-29
Primary Completion
2023-04-29
Completion
2025-04-29

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05577572 on ClinicalTrials.gov